Thermo Fisher Scientific Inc., the world leader in serving science, has announced a strategic collaboration with OpenAI to integrate advanced artificial intelligence (AI) capabilities across its operations. The partnership aims to enhance the speed and efficiency of drug development, helping customers bring new medicines to patients faster and more cost-effectively.
By embedding OpenAI’s APIs (Application Programming Interfaces) into key areas of its business—including product development, service delivery, customer engagement, and operational workflows—Thermo Fisher seeks to accelerate innovation, boost productivity, and reduce complexity across the scientific value chain.
“AI is shaping the future of science. And when combined with our Mission to enable our customers to make the world healthier, cleaner and safer, it is a powerful catalyst to accelerate scientific advancement,” said Marc Casper, Chairman, President, and Chief Executive Officer of Thermo Fisher Scientific. “With OpenAI, we’re further embedding AI across our operations, products and services. Together, we’re building an ecosystem that accelerates scientific breakthroughs and delivers impact for customers, patients and society.”
Key Focus Areas of the Collaboration
Accelerating Clinical Trials:
OpenAI’s advanced AI models will be deployed within Thermo Fisher’s PPD™ clinical research business to significantly reduce clinical trial cycle times. This integration aims to help new therapies reach the market faster, generating meaningful value for the global biopharma industry.
Enhancing Predictive Insights:
By combining OpenAI’s generative capabilities with Thermo Fisher’s scientific expertise, the partnership will help identify drug candidates that are unlikely to succeed earlier in the development process. This will allow customers to redirect resources toward more promising therapeutic opportunities.
Powering the Accelerator™ Drug Development Platform:
The collaboration will integrate AI into Thermo Fisher’s Accelerator™ solution, which provides an end-to-end framework for drug development—from early discovery and clinical research to manufacturing, supply, and commercialization. The goal is to deliver greater speed, simplicity, and scalability for pharmaceutical partners.
Empowering Employees with Frontier AI:
Thermo Fisher will deploy ChatGPT Enterprise internally, enabling colleagues to develop AI fluency and confidence while streamlining workflows and fostering a culture of innovation.
“Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people,” said Brad Lightcap, Chief Operating Officer at OpenAI. “With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients' lives.”
This collaboration marks a significant step in embedding AI into the scientific enterprise, reinforcing Thermo Fisher’s commitment to advancing research, improving patient outcomes, and shaping the future of life sciences through data-driven innovation.
Also Read
